NCT00206726 - Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

DRUG

Alemtuzumab plus Fludarabine

Alemtuzumab (Campath) 30mg subcutaneous (SC) plus Fludarabine (Fludara) 25mg/m² intravenous (IV), Days 1-5 every 28 days

Trial Locations (27)

11768

Northport

15224

Pittsburgh

20422

Washington D.C.

20735

Clinton

30322

Atlanta

33805

Lakeland

35223

Birmingham

37604

Johnson City

39202

Jackson

55417

Minneapolis

60504

Aurora

60637

Chicago

62703

Springfield

70006

Metairie

73505

Lawton

89520

Reno

91595

Burbank

94520

Concord

94704

Berkeley

97239

Portland

94305-5118

Stanford

02115

Boston

03756-0001

Lebanon

08903-2681

New Brunswick

12208-3473

Albany

98431-5000

Tacoma

53226-3596

Milwaukee

All Listed Sponsors

lead

Genzyme, a Sanofi Company

INDUSTRY